Welcome to our dedicated page for Organogenesis Hldgs SEC filings (Ticker: ORGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Organogenesis Holdings Inc. (ORGO) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Capital Market issuer, Organogenesis submits periodic and current reports that describe its financial condition, operating results, clinical programs, governance matters, and capital structure.
Through this page, users can review Form 10-K annual reports and Form 10-Q quarterly reports, which include audited or reviewed financial statements, segment information for its regenerative medicine operations, and detailed discussions of risk factors, research and development spending, and market dynamics for its Advanced Wound Care and Surgical & Sports Medicine product categories. These filings also outline how the company reports net product revenue, operating expenses, cash and cash equivalents, and information about Series A redeemable convertible preferred stock.
Current reports on Form 8-K document material events such as quarterly earnings releases, updates on the Phase 3 randomized controlled trials of ReNu for knee osteoarthritis, plans to request or initiate a Biologics License Application (BLA), and stockholder meeting results. For example, Organogenesis has used Form 8-K to furnish press releases on ReNu clinical data, to describe its intention to pursue a BLA submission pathway, and to report the outcomes of its annual meeting, including director elections and advisory votes on executive compensation.
Investors can also use this page to track governance and capital structure disclosures, including approvals related to the potential issuance of additional Class A common stock upon conversion of Series A Convertible Preferred Stock under Nasdaq listing rules. Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify important financial metrics, clinical program updates, and regulatory milestones without reading every line of each report.
Organogenesis Holdings Inc. vice president of strategy Robert Cavorsi reported a tax-related share transfer. On this transaction, 700 shares of Class A common stock were disposed of at
Organogenesis Holdings Inc. executive Antonio S. Montecalvo reported updated stock transactions related to an equity award. The amended filing corrects the number of Class A Common shares acquired upon vesting of a performance share award and the shares withheld to cover taxes. On February 18, 2026, he was granted 11,330 shares at a price of $0.00 per share and had 3,778 shares withheld at $3.84 per share to satisfy tax obligations. After these adjustments, he directly holds 226,238 Class A Common shares. The amendment states no other changes were made to the original report.
Organogenesis Holdings Inc. President and CEO Gary S. Gillheeney reported updated equity compensation activity. On February 18, 2026, he acquired 188,856 shares of Class A common stock as a grant or award at $0.00 per share, and disposed of 91,311 shares at $3.84 per share to cover tax obligations. The amendment corrects the numbers previously reported for the performance share vesting and related tax-withholding, with no other changes to the original Form 4.
Organogenesis Holdings Inc. Chief Commercial Officer Brian Grow filed an amended insider transaction report. On February 18, 2026, he acquired 48,818 shares of Class A common stock at $0.00 per share through the vesting and settlement of a performance share award, and 11,887 shares were disposed of at $3.84 per share to cover tax obligations. After these adjustments, he directly owns 899,724 shares. The amendment corrects the previously reported share amounts related to this award, with no other changes.
Organogenesis Holdings Inc. Chief Operating Officer Patrick Bilbo filed an amended insider report updating a prior Form 4. The amendment corrects the number of Class A Common Stock shares reported from a performance share award that vested on February 18, 2026 and the related tax withholding. The filing now shows an award acquisition of 49,102 shares at a stated price of $0.00 per share and a tax-withholding disposition of 16,375 shares at $3.84 per share. Following these adjustments, Bilbo directly holds 1,128,312 shares of Class A Common Stock.
Organogenesis Holdings Inc. Chief Financial Officer Francisco David reported amended equity award details. On February 18, 2026, he acquired 44,040 shares of Class A common stock as a grant at no cost, and 14,687 shares were withheld at $3.84 per share to cover tax obligations. This amendment only corrects the share counts previously reported for the award vesting and related tax withholding.
Organogenesis Holdings Inc. executive Robert Cavorsi, Vice President of Strategy, filed an amended insider report updating a prior Form 4. The amendment corrects the number of Class A Common Stock shares acquired upon vesting and settlement of a performance share award and the shares withheld for taxes. On February 18, 2026, he was granted 16,454 shares at $0.00 per share and had 5,487 shares withheld at $3.84 per share to satisfy tax obligations. Following these adjustments, his direct holdings total 276,224 Class A shares. The filing states no other changes were made to the original report.
Organogenesis Holdings Inc. executive Lori Freedman updated her insider holdings following a performance share award. She acquired 43,212 shares of Class A common stock at no cost from the vesting and settlement of a performance share award, and 14,411 shares were withheld to cover related tax obligations. This amended Form 4 corrects the originally reported acquired and tax-withheld share amounts, with no other changes to the prior filing.
Organogenesis Holdings Inc. filed an initial ownership statement for Chief Accounting Officer Patrick McGuire, detailing his direct holdings of Class A common stock and related equity awards. The filing notes that some positions represent restricted stock units granted under the 2018 Equity Incentive Plan, with unvested RSUs scheduled to vest in equal annual installments on December 29, 2026, 2027 and 2028, and on February 15, 2027, 2028 and 2029.
Organogenesis Holdings Inc. provides an in‑depth look at its regenerative medicine business, focused on advanced wound care and surgical and sports medicine products like Apligraf, Dermagraft, PuraPly, NuShield, Affinity, Novachor and ReNu.
The company outlines major shifts in Medicare and CMS policy for skin substitutes, including new 2026 payment structures and the WISeR prior‑authorization model, which are already contributing to a significant year‑over‑year revenue decline in early 2026 and may pressure future utilization and profitability.
Organogenesis also highlights mixed but generally supportive Phase 3 data for its ReNu osteoarthritis program and the start of a rolling BLA, plus a long‑term lease for a new Smithfield, Rhode Island biomanufacturing facility intended to bring Dermagraft production back online and expand capacity from 2027.